Skip to main content

Table 2 Studies reporting exact numbers, odds ratios, or relative risks for various birth outcomes in women with IBD exposed to TNF-α blockers compared with unexposed controls with IBD

From: Safety of TNF-α inhibitors during IBD pregnancy: a systematic review

Author Patients with IBD exposed to TNF-α blockers Controls Spontaneous abortions or stillbirths Preterm delivery Low birth weight Abnormalities/major birth defects/malformations Infections during the first 12 months of life
Johnson et al. [72] 34a 55b 5/34 versus 3/55; OR 2.99 (95% CI 0.67 to 13.41) 2/34 versus 2/53; OR 1.59 (0.21 to 11.9)
Schnitzler et al. [54] 42 78 9/42 versus 12/78; OR 1.5 (0.57 to 3.92) 8/32 versus 8/65; OR 2.38 (0.80 to 7.06) 6/32 versus 9/65; OR 1.44 (0.46 to 4.46) 1/42 versus 1/78; OR 1.87 (0.11 to 30.8)
Casanova et al. [48] 202c 110 20/202 versus 19/110; OR 0.53 (0.27 to 1.04) 8/202 versus 13/110; OR 0.31 (0.12 to 0.77) 12/202 versus 11/110; OR 0.57 (0.24 to 1.33) 2/202 versus 0/110; (no OR or CI)
Mahadevan et al. [51] 79c 291/326 RR 1.29 (0.79 to 2.11); Biologics alone:; RR 2.56 (1.07 to 4.12) RR 1.83 (1.01 to 3.31); Biologics alone:; RR 0.89 (0.54 to 1.47) RR 1.35 (1.01-1.80); Biologics alone:; RR 0.89 (0.70-1.12)
  1. Abbreviations: CI confidence interval, IBD inflammatory bowel disease, OR odds ratio, RR relative risk, TNF tumor necrosis factor.
  2. aPatients with Crohn’s disease, psoriasis, rheumatoid arthritis, and other forms of arthritis.
  3. bControls were unexposed patients with rheumatoid arthritis.
  4. cTNF-α blockers and/or thiopurines or other immunomodulators.